Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $253.83M |
| Gross Profit (TTM) | $218.60M |
| EBITDA | $71.48M |
| Operating Margin | -12.00% |
| Return on Equity | 5.38% |
| Return on Assets | 1.23% |
| Revenue/Share (TTM) | $12.83 |
| Book Value | $48.09 |
| Price-to-Book | 6.22 |
| Price-to-Sales (TTM) | 24.13 |
| EV/Revenue | 26.24 |
| EV/EBITDA | 69.47 |
| Quarterly Earnings Growth (YoY) | 825.00% |
| Quarterly Revenue Growth (YoY) | -31.80% |
| Shares Outstanding | $20.00M |
| Float | $19.55M |
| % Insiders | 2.30% |
| % Institutions | 115.11% |
Volatility is currently expanding
Ligand Pharmaceuticals earns a BUY rating, driven by robust royalty growth and the accretive XOMA acquisition. Filspari's 85% YoY royalty growth and new FSGS indication position it as LGND's leading earnings driver. XOMA's $12.3M Q3 royalty contribution and deep pipeline diversify LGND's revenue and future catalysts.
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning & Analysis Todd Davis - CEO & Director Octavio Espinoza - Chief Financial Officer Lauren Hay Paul Hadden - Senior Vice President of Investments & Business Development Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Glen Santangelo Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Ligand Third Quarter Earnings Call.
Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty. The company also raised its full-year adjusted diluted earnings-per-share outlook while maintaining its revenue guidance.
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference.
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.
Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LGND and any ticker you trade — then tracks every position and per-strategy win rate.
